Antibody Thioether Cross-Linking for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic monoclonal antibodies often suffer from microheterogeneity and degradation issues due to post-translational modifications and environmental factors, limiting their stability and effectiveness in therapeutic applications.
Innovation Solution
Development of macromolecules, specifically antibodies, incorporating thioether cross-links that enhance stability and pharmaceutical properties, including the use of thioether bonds between cysteine residues in heavy and light chains, and the introduction of lanthionine residues to maintain structural integrity and binding specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used, then production and therapeutic application are feasible, but microheterogeneity and degradation occur due to post-translational modifications and environmental factors
Solution Approach 1:
The patent applies preliminary action by introducing thioether cross-links during the antibody production process before the antibody is deployed therapeutically. The cross-linking agents are incorporated into the antibody structure during manufacturing, creating stable inter-chain cross-links that prevent subsequent degradation and microheterogeneity throughout the antibody's shelf life and therapeutic use.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of the antibody through thioether cross-linking. This involves changing the molecular structure from a conventional un-crosslinked antibody to a cross-linked antibody with altered chemical properties. The cross-linking modifies the antibody's molecular weight, structural rigidity, and resistance to degradation, thereby improving stability without compromising therapeutic activity.
2Duration of action of stationary object
If thioether cross-links are introduced to improve stability, then structural integrity and shelf-life are enhanced, but the complexity of the macromolecule increases
Solution Approach 1:
The patent applies local quality by introducing thioether cross-links at specific locations within the antibody structure rather than uniformly throughout. The cross-links are formed at particular cysteine residue positions in the heavy and light chains, creating localized structural reinforcements that improve stability without unnecessarily complicating the entire macromolecule. This targeted approach maintains the antibody's functional regions while enhancing structural integrity.
3Manufacturing precision
If cross-linking agents are used to maintain structural integrity, then binding specificity is preserved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies self-service by utilizing the antibody's own cysteine residues as the cross-linking sites. The thioether cross-links are formed between cysteine residues in different chains (heavy-heavy, light-light, or heavy-light), allowing the antibody structure itself to provide the cross-linking function. This self-cross-linking mechanism preserves binding specificity while simplifying the manufacturing process compared to using external cross-linking agents that would require additional purification steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The incorporation of thioether cross-links and lanthionine residues in antibodies improves their stability, reduces degradation, and maintains antigen-binding specificity, leading to enhanced pharmaceutical properties and prolonged shelf-life.
Implementation Method 1
The association between the four chains involves both covalent and noncovalent interactions. The covalent interactions are disulfide bonds formed between the cysteine residues in the carboxyl terminus of the light chain and the CH1 domain of the heavy chain
Implementation Method 2
In certain embodiments, the thioether cross-links have a structure according to formula I: —OOC—CH(NH—)—R1—S—R2—CH(NH—)—COO—, wherein R1 and R2 are independently side chains of macromolecular residues, such as amino acid residues
Data Source
AI summary
The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.